Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.
about
NPEST: a nonparametric method and a database for transcription start site predictionInfluence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patientsDifferential Evolution approach to detect recent admixture.Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Does Critical Illness Change Levofloxacin Pharmacokinetics?Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal InfectionPharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysisEffect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.Are vancomycin trough concentrations adequate for optimal dosing?Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.Pharmacokinetics of centhaquin citrate in a rat model.Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.Maximally effective dosing regimens of meropenem in patients with septic shock.Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.Pharmacokinetics of centhaquin citrate in a dog model.Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
P2860
Q34142587-FEC2D23B-9511-4869-B339-5A2CD8FCEFC6Q35607704-688492BF-3A23-42AC-A167-DD196188351BQ35674657-5CE7CFE6-6583-49B9-A251-DEEB5BC537D8Q35960852-5CFD56B7-9BF1-40C3-AFCC-529960667F0BQ36644695-545B5F9D-3ED2-46C2-B0B6-CEB251FA8989Q36892839-154B65CA-19B8-4CFE-8D8B-C629E51425F5Q37119964-40C860C6-938F-4F6D-AE65-30C21362F614Q37120024-A0EDF00B-824E-4990-B6CB-2DA463C0F94AQ37287667-D68109D7-6A8E-4E2B-B77F-0896CA565A15Q37287812-8BC6A78E-C95D-4210-9DE1-28E70E818BE5Q37335646-22EE87A6-691B-45D7-A3C3-3B4769345C24Q37358623-01AB280F-E783-48BA-9E25-B643BC1962A4Q37544400-6084ED05-B2FE-4461-91CD-20B11AD65129Q37544422-B64FD943-9DED-4ECF-9682-7324CB4ED865Q38382954-F073588F-3EC7-4F3E-808E-650337C372BBQ38741453-AFE7B6A3-853D-4EB1-898B-1DFDF024D7D8Q38910495-B53691AE-322F-4E0D-9A6C-3A5CFA7A1D57Q39031509-F5E36746-8D06-428B-8A65-24423D2CA771Q39040314-65A0B6B9-2C76-4BDF-B73A-F1A66CD9936FQ39936905-848DFFB0-5A66-41D7-A3AF-663892340AD4Q40149941-94E98B57-3339-40CE-8863-FAC485E9E8A8Q40175198-3B379E3E-B1D0-4F3C-B87B-F9FAD762D245Q40354366-55874479-4B5F-4158-A4A5-251DE8D4C464Q40672214-F373FFEB-5558-4531-9051-805EB21CA131Q41172930-DFEB41B8-0133-4720-84D0-C3BB463DDB3EQ47442689-8CE7B8D6-7F9C-4366-A7B4-7F97DFCBEF9CQ47624900-2008E168-C3DD-472A-8D1F-AF3CAEB9C2DAQ48139759-5CDE5C5F-1186-4EE4-AFB2-F9F1108E63CAQ50660109-9CB06EE9-8C99-41C9-887D-1E19CAE66CCFQ53822956-EACCB28A-22AA-4AD0-AF5E-C7EADB4C29A0
P2860
Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Two general methods for popula ...... d and non-parametric Bayesian.
@en
Two general methods for popula ...... d and non-parametric Bayesian.
@nl
type
label
Two general methods for popula ...... d and non-parametric Bayesian.
@en
Two general methods for popula ...... d and non-parametric Bayesian.
@nl
prefLabel
Two general methods for popula ...... d and non-parametric Bayesian.
@en
Two general methods for popula ...... d and non-parametric Bayesian.
@nl
P2093
P2860
P1476
Two general methods for popula ...... d and non-parametric Bayesian.
@en
P2093
Alan Schumitzky
Alyona Chubatiuk
David Bayard
Jay Bartroff
Michael Neely
Michael van Guilder
Robert Leary
Roger Jelliffe
Tatiana Tatarinova
Walter Yamada
P2860
P2888
P304
P356
10.1007/S10928-013-9302-8
P577
2013-02-13T00:00:00Z